Stock A166480 CORESTEMCHEMON INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company CORESTEMCHEMON Inc.

Equities

A166480

KR7166480004

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
11,650 KRW +0.09% Intraday chart for CORESTEMCHEMON Inc. -1.10% +72.08%
Mar. 26 CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. CI
Mar. 22 CORESTEMCHEMON Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and another investor CI

Business Summary

Corestemchemon Inc, formerly Corestem Inc, is a Korea-based company engaged in the development, production and sale of stem cell therapies for intractable diseases. The Company operates its business through two segments. The Non-clinical Contract Research Organization (CRO) Business segment is engaged in the provision of research and development services such as toxicity (safety) verification and drug efficacy (efficacy) verification in the non-clinical stage. The Cell Therapy Business segment is engaged in the development, production and sale of Lou Gehrig's disease treatments such as Neuronata-R.

Number of employees: 376

Sales per Business

KRW in Million2022Weight2023Weight Delta
Non-clinical Laboratory Agency Services
95.1 %
41,284 89.2 % 32,017 95.1 % -22.45%
Cell Therapy Drugs
4.9 %
5,009 10.8 % 1,640 4.9 % -67.26%

Sales per region

KRW in Million2022Weight2023Weight Delta
South Korea
100.0 %
46,293 100.0 % 33,657 100.0 % -27.30%

Managers

Managers TitleAgeSince
Gyeong-Sook Kim CEO
 Chief Executive Officer 59 -
Tae-Yong Lee CTO
 Chief Tech/Sci/R&D Officer 42 -
Heon-Jeong Lim AUD
 Comptroller/Controller/Auditor 56 -
Gil-Ahn Yang SAM
 Sales & Marketing 68 18-06-30
Gwang-Soon Kwon PRN
 Corporate Officer/Principal 52 17-02-28

Members of the board

Members of the board TitleAgeSince
Gyeong-Sook Kim CEO
 Chief Executive Officer 59 -
Kwan-Hee Hong BRD
 Director/Board Member 65 18-02-28
Sang-Bae Han BRD
 Director/Board Member 59 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 32,870,376 17,454,843 ( 53.10 %) 11,460,416 ( 34.87 %) 53.10 %

Shareholders

NameEquities%Valuation
CORESTEMCHEMON INC.
23.78 %
7,817,638 23.78 % 63 M ₩
Gyeong-Sook Kim
10.60 %
3,483,320 10.60 % 28 M ₩
Si-Hwan Song
0.8883 %
291,981 0.8883 % 2 M ₩
Gwang-Soon Kwon
0.1436 %
47,200 0.1436 % 378 301 ₩
Byung-chul Kim
0.1284 %
42,200 0.1284 % 338 227 ₩
Tae-Yong Lee
0.0608 %
20,000 0.0608 % 160 297 ₩

Holdings

NameEquities%Valuation
CORESTEMCHEMON INC.
23.78%
 7,817,638 23.78% 62,657,274 $

Company contact information

CORESTEMCHEMON, Inc.

2/F, I & C Building 24 Pangyo-ro 255 beon-gil

13486, Seongnam-si

+

http://www.corestem.com
address CORESTEMCHEMON Inc.(A166480)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CORESTEMCHEMON INC. Stock CORESTEMCHEMON Inc.
+72.08% 182M
MODERNA, INC. Stock Moderna, Inc.
+24.92% 48.09B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.18% 40.43B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.36B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.41% 24.89B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.36% 19.01B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.59% 12.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.71% 11.88B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.96% 11.8B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A166480 Stock
  4. Company CORESTEMCHEMON Inc.